Moolec Science (MLECW) Interest Expenses (2023 - 2025)
Moolec Science (MLECW) posted Interest Expenses of $38.1 million for Q2 2025, up 345.76% sequentially from -$15.5 million in Q4 2024, and up 202.7% YoY from $12.6 million in Q2 2024.
Moolec Science (MLECW) Interest Expenses (2023 - 2025) Analysis & Trends
Moolec Science has reported Interest Expenses for 3 years, with the latest figure at $38.1 million in Q2 2025.
- Quarterly Interest Expenses rose 202.7% year-over-year to $38.1 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$16.0 million (changed N/A YoY) and the FY2025 annual result came in at -$41.8 million, down 11.09% from the prior year.
- Interest Expenses improved to $38.1 million in Q2 2025 per MLECW's latest filing, from -$15.5 million in the prior quarter.
- Over five years, Interest Expenses peaked at $38.1 million in Q2 2025 and troughed at -$37.1 million in Q2 2024.
- A 3-year average of $96158.4 and a median of -$454499.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 453.39% in 2024, then soared 202.7% in 2025.
- Over 3 years, Interest Expenses stood at -$14.3 million in 2023, then decreased by 8.37% to -$15.5 million in 2024, then jumped by 345.76% to $38.1 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $38.1 million, -$15.5 million, and -$550170.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.35 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Jun 30, 2025 | 38.08 Mn |
| Jun 30, 2025 | 38.08 Mn |
| Dec 31, 2024 | -15.49 Mn |
| Dec 31, 2024 | -15.49 Mn |
| Sep 30, 2024 | -550,170.00 |
| Sep 30, 2024 | -550,170.00 |
| Jun 30, 2024 | -37.08 Mn |
| Jun 30, 2024 | -37.08 Mn |
| Mar 31, 2024 | -358,828.00 |
| Mar 31, 2024 | -358,828.00 |
| Dec 31, 2023 | -14.30 Mn |
| Dec 31, 2023 | -14.30 Mn |
| Sep 30, 2023 | -99,419.00 |
| Sep 30, 2023 | -99,419.00 |
| Jun 30, 2023 | 30.57 Mn |
| Jun 30, 2023 | 30.57 Mn |